COMPANY PROFILE

Outpace Bio

Revolutionizing cell therapy with protein design, Outpace reprograms immune cells to make better decisions inside patients, enhancing cell therapy persistence and overcoming biology barriers to cancer…

Seattle, United StatesFounded 2020Biotech & Life Sciences

Valuation $500M–1B Last recorded · 2024

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Outpace Bio

Outpace Bio is a biotech startup that is revolutionizing cell therapy through innovative protein design. The company aims to cure solid tumors by creating new proteins that can guide cells to recognize and eliminate cancer in the body. The company's founders have pioneered a new era in protein design, shifting from designing structures to creating new biological functions.

Outpace Bio's business model revolves around solving three key problems in curing solid tumors: the tumor's suppression of our immune response, the limited persistence of cell therapy, and the limited potency, safety, and specificity of cell therapy. To address these issues, the company has developed technologies that stimulate productive immune responses, enable potent and persistent cell therapy activity, and maximize the potency, safety, and specificity of cell therapies across diverse cancer indications.

The company uses AI-powered protein design to create proteins that program engineered cells for improved function inside patients. These proteins are then combined to develop cell therapy products with curative potential. Outpace Bio's platform technologies can power any cell type and manufacturing approach, making it a versatile player in the biotech industry.

The company operates in the biotech market, serving clients in the medical and healthcare sectors. It generates revenue by developing and selling its innovative cell therapy products and technologies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Seattle, United States
Employees: 73
Open positions: 1
Dealroom signal: 76.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Technology: Artificial Intelligence
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Aug 2024	$144M	$576M	Qatar Investment Authority · Artis Ventures · Breton Capital Management · Abstract Ventures	↗
SERIES AOther financing	Mar 2023	$25M	$100M	Bristol-Myers Squibb · Playground Global · Civilization Ventures · Sahsen Ventures	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Outpace Bio website traffic

Latest recorded traffic for Outpace Bio is 3.7K monthly website visits, down 17.8% over the last three months. Outpace Bio's team grew 7.4% over the past year.

Latest monthly visits3.7K 3-month web change-17.8% 1-year team growth+7.4%

Monthly website visitsDec 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DBDiffuse BioWe're building push-button software for drug design, driven by breakthroughs in generative AI	San Francisco, United States	Operational	11	$125K	$500K
MOMoleculeMindA leading AI protein design platform company	Haidian, China	Operational
ELEarendil LabsAI Solutions to Protein-based Therapeutics	China	Operational
ATApertura Gene TherapyLeverages ML to engineer novel capsids, gene regulatory elements to simultaneously enhance gene therapies	New York City, United States	Operational
MTMatwings TechnologyLeveraging its independently developed general AI for protein design, AccelProtein	Minhang District, China	Operational
ATAukera TherapeuticsBiotech company that develops novel therapeutics for patients suffering from mTOR protein related diseases	Basel, Switzerland	Operational
ABAtavistik BioPrecision allosteric therapeutics for oncology and rare diseases.	Cambridge, United States	Operational
ABAperiam BioTaking the guesswork out of biotechnology with computer vision that illuminates critical parts of protein chemistry	New York City, United States	Operational